A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers

The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other hematologic and solid cancers. Based on their capacity...

Descripción completa

Detalles Bibliográficos
Autores principales: Diesch, Jeannine, Zwick, Anabel, Garz, Anne-Kathrin, Palau, Anna, Buschbeck, Marcus, Götze, Katharina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915187/
https://www.ncbi.nlm.nih.gov/pubmed/27330573
http://dx.doi.org/10.1186/s13148-016-0237-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915187/
https://www.ncbi.nlm.nih.gov/pubmed/27330573
http://dx.doi.org/10.1186/s13148-016-0237-y

Ejemplares similares